BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:53 PM
 | 
Jun 10, 2010
 |  BC Extra  |  Top Story

FDA panel backs fingolimod

FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 25-0 that Novartis AG (NYSE:NVS; SIX:NOVN) demonstrated that fingolimod ( FTY720) was effective at reducing the clinical exacerbations of multiple sclerosis and that the safety of the 0.5 mg dose justified approval. The panel voted 21-3...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >